LOXL2 emerged as one of the most markedly and consistently altered catalysts for the formation of cross-links in fibrillar elastin and collagens thereby generating considerable attention in an ECM-associated pathology such as IPF [23]. Here, LOXL2 is linked to idiopathic pulmonary fibrosis.